Cellutech (B10x)
Plant compounds without plants
Cellutech unlocks nature's most powerful bioactive plant compounds through a novel bio-manufacturing platform. By producing bio-identical plant compounds at scale, we transform supply chain issues across pharmaceutical, agricultural and nutraceutical industries, creating new commercial opportunities. In close collaboration with its industry partners, Cellutech initially targets high-value bioactives with a limited GMP supply and significant clinical relevance. Cellutech’s biomanufacturing platform enables the industry to access rare compounds without the need for extensive agricultural resources, making cutting-edge bioactives commercially viable and scalable for the first time.
Achievements:
Established Proof of concept.
Commercial Partners.
External pre-seed investment attraction, seed round on-track.
Joakim Wisting, Founder CEO; Christopher Wakefield, Founder CFO; Gustavo De Cerqueira, Founder Scientific Adviser; Marina Alonso, Founder CSO; Andrew Heath, CCO; Nathan Taylor, Founder BDM.